INTRODUCTION {#sec1-1}
============

Most SVT episodes can be terminated with vagal maneuvers or intravenous (IV) adenosine bolus. Rarely, SVT can be refractory to initial treatment with adenosine or be recurrent after only brief conversion.\[[@ref1]\] There is no well-defined treatment algorithm for these cases.

Intravenous amiodarone is a commonly used antiarrhythmic medication recommended for management of refractory arrhythmias in both pediatric and advanced life support algorithms (PALS, ALS).\[[@ref2][@ref3]\] The recommendation to use amiodarone for refractory arrhythmias in pediatric population is extrapolated from adult studies. The PALS algorithm is to consider either IV amiodarone (5 mg/kg IV/IO over 20-60 minutes and can be repeated twice) or procainamide for SVT if it does not respond to adenosine or electrical cardioversion. IV amiodarone does have adverse effects, including hypotension, acute liver dysfunction, and serious pulmonary toxicity.\[[@ref4]\] There have been very few reported cases of cardiovascular collapse in literature following amiodarone infusion.\[[@ref5][@ref6][@ref7]\] We report a case of severe cardiovascular collapse during amiodarone infusion that was rescued with ECMO and intravenous procainamide infusion.

CASE REPORT {#sec1-2}
===========

A 7-week-old healthy female infant was admitted to an outside hospital with vomiting of two-week duration along with poor feeding and cold extremities noticed by her parents on the day of admission.

An initial diagnosis of SVT with left bundle branch block was made \[[Figure 1](#F1){ref-type="fig"}\]. There was no evidence of either pre-excitation or non-conducted P waves on the electrocardiogram during brief periods of sinus rhythm, suggesting that it was due to an AV node-dependent mechanism. The presence of P waves suggested that it was likely due to a concealed accessory pathway \[[Figure 2](#F2){ref-type="fig"}\]. The SVT briefly responded to multiple administrations of adenosine with immediate recurrence. Electrical cardioversion was not attempted because it was clear that "conversion" to sinus rhythm was not the limiting factor for this patient, and that the focus needed to be on the maintenance of sinus rhythm. Therefore, she was started on an esmolol infusion, after which she developed hypotension. At the same time, she was noted to have metabolic acidosis. At this point, she was intubated, started on mechanical ventilation, and transferred to our centre for further management.

![Narrow complex tachycardia with left bundle branch block](APC-8-50-g001){#F1}

![Normal sinus rhythm following treatment.\
ECMO: Extracorporeal membrane oxygenation, IV: Intravenous, PALS: Pediatric advanced life support, SVT: Supraventricular tachycardia](APC-8-50-g002){#F2}

During transport esmolol infusion was discontinued secondary to bradycardia and hypotension and with this, the SVT recurred. Upon arrival at our institution, the esmolol infusion was restarted, but she again developed hypotension with bradycardia; therefore, it was discontinued and an amiodarone bolus of 5 mg/kg was given IV over 60 minutes. This converted her rhythm from persistent SVT to intermittent runs of SVT. Since it appeared that amiodarone was helping to control the SVT, a second bolus of 5 mg/kg was started with a plan to infuse over 60 minutes. Throughout this time she had a significant metabolic acidosis with pH around 7.2 on the blood gas and lactate of above 15 mmol/L. Her echocardiogram showed severe left ventricular dysfunction while she was in sinus rhythm between episodes of SVT. During the second bolus of amiodarone she suddenly developed severe bradycardia and hypotension following which cardio-pulmonary resuscitation (CPR) was commenced. She was successfully placed on to venoarterial extra cardiac membrane oxygenation (ECMO) support. IV procainamide bolus (10 mg/kg) was given followed by an infusion initially at 20 mcg/kg/min with gradual increase to 60 mcg/kg/min (second bolus of 5 mg/kg in between) leading to conversion of SVT to sinus rhythm after about 14 hours from the initial bolus.

She was decannulated from the ECMO circuit on day 4 on infusions of milrinone and procainamide. On day 5, she was transitioned to oral flecainide followed by successful extubation from mechanical ventilation. A metabolic and genetic workup for cardiomyopathy was negative. During the hospital stay she also developed acute kidney injury, transient transaminitis, and thrombocytopenia all of which resolved gradually. She had normal biventricular function at discharge. At follow up 2 months post discharge, she has done well on oral flecainide and enalapril.

DISCUSSION {#sec1-3}
==========

There is no commonly accepted treatment regime for cases refractory to initial therapy of SVT using either vagal maneuvers or adenosine. Therapies used in the context of refractory SVT include IV and oral digoxin, IV and oral beta-blockers, oral flecainide, oral sotalol, IV procainamide, IV amiodarone, electrical cardioversion, and transesophageal overdrive pacing. Calcium channel blockers are now rarely used for acute refractory SVT in infancy as they were reported to cause acute collapse and even death in infants.\[[@ref8]\] While IV sotalol is available, there has been very little experience with its use. Flecainide is available only in oral form in the United States. Furthermore, all the IV antiarrhythmic medications available except digoxin (beta blockers, calcium blockers, procainamide, sotalol, and amiodarone) can cause acute hypotension. While hypotension associated with amiodarone is well documented, few cases of cardiovascular collapse in neonates have been reported.\[[@ref6]\]

There are no clear guidelines regarding management of hemodynamically unstable patients with refractory SVT other than PALS recommendation of use of amiodarone or procainamide.\[[@ref2]\] Amiodarone is a complex drug with multiple mechanisms of action and has been called the "king" of antiarrhythmics. However, the pre-eminence of amiodarone has recently been questioned.\[[@ref9]\]

Amiodarone is thought to cause hypotension due to histamine release secondary to the solvent polysorbate 80.\[[@ref10]\] Certain canine species, especially dogs, have been shown to be intolerant of this commonly used diluent, and some have suggested that it may be poorly tolerated by humans also.\[[@ref11]\] Recently, a newer IV form of amiodarone (PM101) has been approved by FDA that uses cyclodextrin instead of polysorbate 80 and benzyl alcohol as solvent in order to reduce hemodynamic side effects and improve compatibility with other medications.\[[@ref12]\]

Amiodarone also has calcium channel-blocking properties, and infants have been shown to tolerate calcium channel blockers poorly.\[[@ref13]\] A number of reports of cardiovascular collapse with IV verapamil led to recommendations against its use in infants.\[[@ref8][@ref14]\] Whether pre-treatment with IV calcium can mitigate the hemodynamic effects of amiodarone is not known. Our patient did not tolerate either esmolol or amiodarone, and this likely represents that the patient was in a fragile state with no cardiac output reserve. Radiofrequency ablation was not considered due to age and size of the child and also initial favorable response to intravenous amiodarone, which prompted us to administer the second bolus.

While procainamide was successful in controlling the arrhythmia in our patient, it too can cause negative inotropy and be deleterious for patients with ventricular dysfunction.\[[@ref15]\] In a recent paper, Chang *et al*. suggested that procainamide may be more successful in controlling SVT than amiodarone with no increase in adverse effect frequency.\[[@ref16]\] However, as expounded in an accompanying editorial by Saul and LaPage, the study had many flaws and in particular, the two population groups were not uniformly distributed as more cases with underlying congenital heart disease were in the amiodarone group.\[[@ref17]\]

CONCLUSION {#sec1-4}
==========

Our case illustrates the potential dangers of using IV amiodarone in hemodynamically unstable infants with refractory SVT. It is possible that a newly released form of amiodarone (PM101) may avoid the adverse effects associated with the currently available form of amiodarone in children.
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